INTRODUCTION

Interleukin-17 (IL-17) is a potent pro-inflammatory cytokine that is produced by activated T lymphocytes (1). Th17 cells are a subset of CD4+ T lymphocytes named after their hallmark cytokine IL-17 (2), which represents the prototype of a recently identified cytokine family comprising six members (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F) and five receptors (IL-17RA, IL-17RB, IL-17RC, IL-17RD, IL-17RE). IL-17 production is stimulated by IL-23 (3).

OBJECTIVES: To determine the serum interleukin-17 (IL-17) levels in childhood-onset systemic lupus erythematosus patients and to evaluate the association between IL-17 and clinical manifestations, disease activity, laboratory findings and treatment.

METHODS: We included 67 consecutive childhood-onset systemic lupus erythematosus patients [61 women; median age 18 years (range 11–31)], 55 first-degree relatives [50 women; median age 40 years (range 29–52)] and 47 age- and sex-matched healthy controls [42 women; median age 19 years (range 6–30)]. The childhood-onset systemic lupus erythematosus patients were assessed for clinical and laboratory systemic lupus erythematosus manifestations, disease activity [Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)], cumulative damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index] and current drug use. Serum IL-17 levels were measured by an enzyme-linked immunosorbent assay using commercial kits.

RESULTS: The median serum IL-17 level was 36.3 (range 17.36–105.92) pg/mL in childhood-onset systemic lupus erythematosus patients and 29.47 (15.16–62.17) pg/mL in healthy controls (p=0.009). We observed an association between serum IL-17 levels and active nephritis (p=0.01) and migraines (p=0.03). Serum IL-17 levels were not associated with disease activity (p=0.32), cumulative damage (p=0.34), or medication use (p=0.63).

CONCLUSION: IL-17 is increased in childhood-onset systemic lupus erythematosus and may play a role in the pathogenesis of neuropsychiatric and renal manifestations. Longitudinal studies are necessary to determine the role of IL-17 in childhood-onset systemic lupus erythematosus.

KEYWORDS: Interleukin-17; Childhood-onset systemic lupus erythematosus.

IL-17 promotes inflammation by inducing local chemokine and cytokine secretion (4) and is essential for the clearance of certain pathogens such as bacteria and fungi. Moreover, IL-17 has been linked to the instigation of immune-mediated organ damage in the context of several autoimmune diseases (3). The frequency of IL-17-producing T cells is increased in the peripheral blood of adult systemic lupus erythematosus (SLE) patients (4,6), and IL-17 production is abnormal in SLE patients (4–11). IL-17 levels are increased in adult SLE sera and correlate with disease activity (9, 12–15).

SLE is a heterogenic autoimmune inflammatory disease characterized by a wide spectrum of clinical manifestations and abnormal production of high-titer autoantibodies directed towards nuclear autoantigens (5,7,8). Although the pathogenesis of SLE is not completely clear, genetic, environmental and hormonal factors play key roles in susceptibility and heterogeneous clinical manifestations (5). Childhood-onset SLE (cSLE) has a clinically different phenotype than adult-onset SLE (9). For instance, cSLE patients have increased kidney and central
immunofluorescence using HEp-2 cells as the substrate and were diagnosed on the basis of the renal items of the SLE record. Active nephritis was defined according to the ACR guidelines (19).

Therefore, the aim of our study was to determine the association of IL-17 with disease activity, laboratory findings and treatment features.

METHODS

Subjects
Sixty-seven consecutive cSLE patients followed at the Pediatric Rheumatology Unit of the State University of Campinas were invited to participate in this cross-sectional study. Patients were included in the present study if they (i) fulfilled at least four of the American College of Rheumatology (ACR) criteria (17), (ii) were younger than 16 years of age at disease onset, and (iii) had a follow-up duration of at least 6 months. Forty-seven first-degree relatives were included in this study. Fifty-five healthy controls without a history of any chronic disease (including a personal history of autoimmune diseases) were included as the control group.

The healthy controls were matched for age, sex and demographic background. This study was approved by the ethics committee at our institution, and written informed consent was obtained from each participant and/or legal guardian.

Clinical, laboratory and treatment features
The medical histories and clinical and serological features of each patient were reviewed in medical charts. The variables included in this database were the disease onset (defined as the age at which the first symptoms clearly attributable to SLE occurred), age at diagnosis (defined as the age at which the patients fulfilled four or more of the 1982 revised criteria for the classification of SLE (17)), and follow-up time (defined as the time from disease onset until July 2011).

All clinical manifestations and laboratory findings were recorded on the day of blood withdrawal. Active nephritis was diagnosed on the basis of the renal items of the SLE Disease Activity Index (SLEDAI) (18): proteinuria exceeding 0.5 g/24 hours and active urinary sediment [urinary casts, hematuria (>5 red cells/high power field [HPF]) and pyuria (>5 leucocytes/HPF] in the absence of urinary tract infections).

Nephrotic syndrome was defined as proteinuria in excess of 3 g/day. Hematological abnormalities were ascribed to lupus only in the absence of bone-marrow suppression (leukopenia <4000 cells/mm³, thrombocytopenia <100,000 cells/mm³, and hemolytic anemia). We also assessed the presence of malar rash, discoid lesions, subacute cutaneous lesions, cutaneous vasculitis, photosensitivity, oral ulcers, arthritis, and serositis. Neurological and psychiatric involvement was defined according to the ACR guidelines (19).

The treatment prescribed at the time of blood withdrawal and any adverse events related to medication use were recorded. Doses of oral and parental corticosteroids were analyzed and converted to the equivalent doses of prednisone.

Antinuclear antibodies (ANA) were measured by indirect immunofluorescence using HEp-2 cells as the substrate and were regarded as positive if higher than 1:40. Double-stranded DNA (dsDNA) antibodies were determined by indirect immunofluorescence using Crithidia as the substrate and were considered positive if higher than 1:10. Precipitating antibodies to extractable nuclear antigens (ENA), including Ro (SSA), La (SSB), and Sm, were detected using a standardized enzyme-linked immunosorbent assay (ELISA) method and were considered positive if higher than 1.80. IgG- and IgM-isotype anticitrullinolipid antibodies (aCL) were measured using an ELISA (20). Lupus anticoagulant (LA) activity was detected by coagulation assays in platelet-free plasma obtained by double centrifugation, following the recommendation of the subcommittee on LA of the Scientific and Standardization Committee of the International Society of Thrombosis and Homeostasis (21). These measurements were performed twice at a 12-week interval.

Diseases Activity/Cumulative Damage Evaluation
Disease activity was measured by the SLEDAI 2000 (SLEDAI-2K) (18). The SLEDAI-2K comprises 24 weighted items grouped into 9 domains, representing organ systems.

Cumulative SLE-related damage was identified in all patients using the Systemic Lupus International Collaborating Clinics (SLICC)/ACR Damage Index (SDI) at the time of blood withdrawal. SDI scores range from 0 to 47. Damage was considered to be present if scores were ≥ 1.23.

Mood and anxiety evaluation
All subjects completed the Beck Depression Inventory (BDI) (24) and Beck Anxiety Inventory (BAI) (25) at study entry. For patients under sixteen years old, the Children’s Depression Inventory (CDI) was applied. These scales comprise 21 items, each describing a common symptom of depression/anxiety. The respondent is asked to rate how much he or she has been bothered by each symptom over the past month on a 4-point scale, ranging from 0 to 3. The items are summed to obtain a total score that can range from 0 to 63. The cutoffs used for the BDI are as follows: 0–13: no/minimal depression; 14–19: mild depression; 20–28: moderate depression; and 29–63: severe depression. For the BAI, the cutoffs are as follows: 0–7: no/minimal level of anxiety; 8–15: mild anxiety; 16–25: moderate anxiety; and 26–63: severe anxiety. The cutoff used for the CDI was 17.

IL-17 assay
Blood samples were collected from all participants, allowed to clot for 30 min at room temperature, and centrifuged at 3000 rpm for 15 min. Separated sera were kept in aliquots at –80 C until assayed. None of the samples were taken during an episode of acute or chronic infection (20). Serum IL-17 levels were measured by ELISA, using commercially available kits from R&D Systems (London, UK), in accordance with the manufacturer’s instructions. The detection range for IL-17 was 31.2–2000 pg/ml, with a sensitivity of 15 pg/ml (human IL-17 kit).

Statistical analysis
All statistical analyses were performed using the Systat 12 software and SPSS Statistics 17.0 software, and the results are given as the median and range. The Kruskal-Wallis test was used to compare cytokine levels between groups. Spearman’s correlation was used to correlate continuous variables (e.g., cytokine levels and SLEDAI, SDI, BDI and
BAI scores). Cytokine levels and categorical variables were compared using the Mann–Whitney U test. The level of significance was set to \( p < 0.05 \).

**RESULTS**

Demographics
We included 67 consecutive cSLE patients. Sixty-one (91.04%) were female, with a median age of 18 years (range 11–31). The median disease duration was 5 years (range 0–25). We included 55 first-degree relatives with a median age of 40 years (range 29–52) (Table 1). The control group comprised 47 healthy volunteers (42 women) with a median age of 19 (range 6–30). The patients and healthy controls were statistically comparable in terms of age and sex (Table 1).

Clinical, laboratory and treatment features
At the time of study entry, 35 (52.2%) cSLE patients had active disease (SLEDAI \( \geq 4 \)), with a median SLEDAI score of 8 (range 4–24). Patients with inactive disease \([N=32 (47.8\%)]\) had a median SLEDAI score of 0 (range 0–2). Active nephritis (35.8%), new malar rash (8.9%), new alopecia (4.5%), cutaneous vasculitis (4.5%) and migraine (4.5%) were the most frequently observed clinical manifestations (Table 2).

At the time of blood withdrawal, 6 (8.9%) patients were not taking any medication. Fifty-nine (88%) patients were receiving prednisone, 37 (55.2%) were receiving hydroxychloroquine, and 26 (38.8%) patients were receiving other immunosuppressive drugs.

With regard to mood and anxiety disorders, 41 (61%) cSLE patients showed no anxiety symptoms, 16 (24%) had mild symptoms, 6 (9%) had moderate symptoms and 4 (6%) had severe symptoms. For depression, 59 (88%) cSLE patients showed no depression symptoms, 5 (8%) had mild depression, 1 (1%) had moderate depression, and 2 (3%) had severe depression (Table 3).

### Table 1 - Demographic and clinical characteristics and IL-17 levels of the patients and controls included in the study.

|                                      | Childhood-onset SLE patients (N=67) | First-degree relatives (N=55) | Healthy controls (N=47) |
|-------------------------------------|------------------------------------|-------------------------------|-------------------------|
| **Sex**                             |                                    |                               |                         |
| Female                              | 61 (91.04%)                        | 50 (90.90%)                   | 42 (89.36%)             |
| **Age (years)**                     | 18 (range 11–31)                  | 40* (range 29–52)            | 19 (range 6–30)         |
| **Disease duration (years)**        | 5 (range 0–25)                    |                               |                         |
| **SLEDAI**                          | 4 (range 0–24)                    |                               |                         |
| **Active disease N=35**             | 8 (range 4–24)                    |                               |                         |
| **Inactive disease N=32**           | 0 (range 0–2)                     |                               |                         |
| **SDI**                             | 0 (range 0–3)                     |                               |                         |
| **Treatment**                       |                                    |                               |                         |
| No medication                       | 6 (8.9%)                           |                               |                         |
| Prednisone                          | 61 (91.1%)                        |                               |                         |
| Dose (mg median/range)              | 15 (0–60)                         |                               |                         |
| Hydroxychloroquine                  | 37 (55.2%)                        |                               |                         |
| Immunosuppressive drugs             | 26 (38.8%)                        |                               |                         |
| Azathioprine                        | 16 (23.8%)                        |                               |                         |
| Cyclophosphamide                    | 3 (4.4%)                          |                               |                         |
| Cyclosporine                        | 5 (7.7%)                          |                               |                         |
| Methotrexate                        | 1 (1.5%)                          |                               |                         |
| Mycophenolate mofetil               | 1 (1.5%)                          |                               |                         |
| **Clinical finding**                |                                    |                               |                         |
| Nephritis                           | 24 (35.8%)                        |                               |                         |
| Rash malar                          | 6 (8.9%)                          |                               |                         |
| Alopecia                            | 3 (4.5%)                          |                               |                         |
| Vasculitis                          | 3 (4.5%)                          |                               |                         |
| Migraine                            | 3 (4.5%)                          |                               |                         |
| IL-17 (pg/ml)                       | 36.3* (17.36–105.92)              | 32.22 (18.93–88.54)          | 29.47* (15.16–62.17)    |

* \( p < 0.05 \)

### Table 2 - Serum IL-17 levels compared with the main clinical manifestations.

| Clinical Manifestation | Median (pg/mL) | IQR    | P-value |
|------------------------|----------------|--------|---------|
| Malar Rash             |                |        | 0.5     |
| Yes (N=6)              | 37.11          | 10.28  |         |
| No (N=61)              | 36.30          | 12.66  |         |
| Alopecia               |                |        | 0.1     |
| Yes (N=3)              | 29.47          | 12.26  |         |
| No (N=64)              | 36.30          | 12.26  |         |
| Cutaneous manifestation|                |        | 0.2     |
| Yes (N=8)              | 33.16          | 12.93  |         |
| No (N=59)              | 36.30          | 12.78  |         |
| Nephritis              |                |        | 0.01*   |
| Yes (N=24)             | 36.86          | 16.41  |         |
| No (N=43)              | 21.31          | 11.60  |         |
| Vasculitis             |                |        | 0.9     |
| Yes (N=4)              | 39.49          | 12.55  |         |
| No (N=63)              | 35.27          | 12.55  |         |

* \( p < 0.05 \)

**IL-17 assay**

The median serum IL-17 levels were 36.3 (range 17.36–105.92) pg/mL in the cSLE patients and 29.47 (15.16–62.17) pg/mL in the healthy controls \( (p=0.009) \). No differences were found between the serum levels of the patients and first-degree relatives (median 32.22 pg/mL, range: 18.93–88.54 pg/mL; \( p=0.41 \)) or between the healthy controls and first-degree relatives \( (p=0.11) \) (Figure 1).

Serum IL-17 levels were significantly increased in cSLE patients with migraines \( (p=0.03) \) and with active nephritis \( (p=0.01) \). However, serum IL-17 levels were not associated with disease activity \( (p=0.32) \), cumulative damage \( (p=0.34) \), anxiety \( (p=0.42) \) or depression \( (p=0.42) \). Serum IL-17 levels did not differ between patients with and without immunosuppressant use \( (p=0.63) \). Upon analyzing each individual medication, no associations were observed.
Recently, Th17 cells have been identified as a new T cell subset; the signature cytokines secreted by Th17 cells include IL-17, IL-17F, IL-21, and IL-22 (2,10,11). This array of cytokines and chemokines, including IL-17, IFN-γ, and IL-1β (29). We observed an increase in serum IL-17 levels in cSLE patients compared with healthy controls. Our data also corroborate some studies in adult SLE patients (6,10,12–15, 27,28) and cSLE patients (9).

The association between IL-17 levels and disease activity remains controversial (9,10,12–15). Although some studies observed a positive association, we and other studies have found no association between IL-17 levels and disease activity (27,28). These diverse findings may be explained by the heterogeneity of clinical and laboratory manifestations in SLE, the different sample size in the above-mentioned studies and variations in the principle and sensitivity of the ELISA tests.

We detected higher IL-17 levels in SLE patients with nephritis. Our data are in agreement with previous studies suggesting that IL-17 could contribute to the pathogenesis of kidney involvement in SLE patients (13,28,30). Support for the pathogenic role of IL-17 derives from the fact that IL-17-producing T cells have been observed in the kidneys of patients with lupus nephritis (29). IL-17 is mostly produced by CD4+, CD8+, CD4–/CD8–, γδ T cells, and Th17 cells. In human lupus nephritis, IL-17-expressing T cells migrate to the kidneys and contribute to inflammatory processes (28,29,31). However, a recent study with cSLE patients did not demonstrate an association between IL-17 and nephritis (9). These findings may be due to the smaller number of patients included or to a different disease duration.

Studies in animal models have shown that T cells expressing IL-17 infiltrate the kidneys of SLE patients. A significant proportion of these cells are CD3+CD4+CD8– DN T cells (26). Additionally, the authors showed that DN T cells from MRL/lpr mice express high levels of IL-17 and that as the disease progressively worsens, IL-17 and IL-23 receptor expression increases in lymphocytes (26).

In another study, IL-23R–deficient lupus-prone C57BL/6–lpr/lpr mice displayed decreased numbers of CD3+CD42CD82 cells and IL-17A–producing cells in the lymph nodes and produced less anti-DNA antibodies. Additionally, clinical and pathological measures of lupus nephritis were abrogated. This experimental study clearly shows the importance of IL-23R-mediated signaling in the development of lupus nephritis and proposes the use of appropriate biologics to treat the disease (32).

A recent study demonstrated that Th17 cells react to CNS autoantigens and manifest a higher migratory capability to the CNS parenchyma compared with other T cell subpopulations due to their ability to penetrate the blood-brain barrier (11). CNS involvement is frequently observed in cSLE patients (33). In our study, we observed an association between increased IL-17 levels and migraines. To date, no studies in the literature have explored this association.

Previous studies have demonstrated an association between mood disorders and IL-17 levels (34,35). The first study observed increased IL-17 levels in patients with rheumatoid arthritis and anxiety, and IL-17 levels were independently associated with higher anxiety scores (34). Another study observed increased IL-17 levels in patients with mood disorders compared with healthy controls (35). In our study, no association between IL-17 and mood disorders was observed. However, we evaluated mood disorders with a self-evaluation questionnaire of symptoms of depression/anxiety, which is not a diagnostic tool; this may have influenced the negative results.

A recent study with a cSLE cohort observed a correlation between IL-17 levels and disease activity and cutaneous and hematological manifestations (9). We did not observe any of these findings in our cohort. This can be explained by the different genetic background, different disease duration and different sample size (we had a larger number of patients).

Similarly to previous studies, we did not observe differences in IL-17 levels according to the use of immunosuppressants (27,36).

SLE is an autoimmune disease, and although genetic susceptibility contributes to its inheritance, environmental factors are also important disease triggers (37). Previous studies have shown that healthy SLE family members have a significantly higher risk of developing SLE or other

| Neuropsychiatric Manifestation | Median (pg/mL) | IQR | P-value |
|-------------------------------|----------------|-----|---------|
| BAI (N=26)                    | 36.86          | 10.90 | 0.4     |
| No (N=41)                     | 38.05          | 11.67 |         |
| BDI (N=8)                     | 36.58          | 9.29  | 0.4     |
| No (N=59)                     | 36.88          | 11.85 |         |
| Migraine (N=3)                | 36.58          | 13.55 | 0.03*   |
| No (N=64)                     | 28.33          | 12.12 |         |

*p < 0.05

Figure 1 - Serum IL-17 levels observed in the three groups included in this study.

Table 3 - Serum IL-17 levels compared with the main neuropsychiatric manifestations.
autoimmune diseases (37,38). However, the IL-17 levels in first-degree relatives have never been studied. In our study, we observed that the IL-17 levels in first-degree relatives were elevated compared with controls, but this value was not significant.

In summary, IL-17 may play a role in the pathogenesis of neuropsychiatric and renal manifestations in SLE patients. Longitudinal studies with regular serum analysis are necessary to determine the role of IL-17 in SLE.

ACKNOWLEDGMENTS

Foundação de Amparo à Pesquisa do Estado de São Paulo/Brasil (FAPESP 2008/20917-4, 2010/13636-2 and 2012/21071-0), Conselho Nacional de Desenvolvimento Científico e Tecnológico/Brasil (CNPq 300447/2009-4, 471431/2011-0; 302055/2012-8; 473329/2013-5).

AUTHOR CONTRIBUTIONS

Pelicari KO, Marini R and Appenzeller S designed the study and were also responsible for data collection, data analysis and manuscript writing. Postal M, Siqueira NA were responsible for data collection, data analysis and manuscript writing. Costall LTIL was responsible for the study design, data analysis and manuscript writing.

REFERENCES

1. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171(11):6173–6, http://dx.doi.org/10.4049/jimmunol.171.11.6173.
2. Yap DYH, Lai KN. Cytokines and their roles in pathogenesis of systemic lupus erythematosus (SLE). J Clin Immunol. 2010;30(2):221–230, http://dx.doi.org/10.1007/s10875-009-9533-3.
3. Nalbandian A, Crispín JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus. Lupus. 2012;21(10):1055–1062, http://dx.doi.org/10.1177/0961203312451200.
4. Liu Y, Ho RC, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. J Neuroimmunol. 2010;229(1–2):212–218, http://dx.doi.org/10.1016/j.jneuroim.2010.07.018.
5. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL-22 levels, but not increased IL-17 and IL-23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2009;68(4):604–609, http://dx.doi.org/10.1136/ard.2008.097989.
6. Niewold TB, Hua J, Lehn TJ, Harley CB, Crow MK. High serum IL-17A antibody activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8(6):492–502, http://dx.doi.org/10.1038/sj.gene.6364408.
7. Niewold TB, Adler JE, Glenn SB, Lehn TJ, Harley CB, Crow MK. Association between serum levels of pro-inflammatory alpha-1antitrypsin in patients with systemic lupus erythematosus. Rheumatology. 2008;47(7):2113–2119, http://dx.doi.org/10.1093/aje/kwn087.